CT SB00191

Department of Mental Health and Addiction Services must establish a psychedelic-assisted therapy pilot program administered by a Connecticut medical school, within available appropriations

Program provides MDMA-assisted or psilocybin-assisted therapy as part of FDA-approved research under 21 CFR 312

Qualified patients must be 18 or older, meet institutional review board clinical eligibility criteria, and be Connecticut residents who are veterans, retired first responders, or direct care health care workers

Removes the previous January 1, 2023 deadline and eliminates the provision that would have ended the program upon DEA approval of MDMA and psilocybin for medical use

Effective July 1, 2026; received Joint Favorable report from Public Health Committee